3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms
- PMID: 2563750
- DOI: 10.1007/BF01250639
3H-spiperone binding sites in post-mortem brains from schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms
Abstract
In post-mortem putamen samples from 27 schizophrenics and 27 controls D2 receptors were measured by Scatchard analysis using 3H-spiperone as a ligand. Maximum number of binding sites (Bmax) and apparent dissociation constant (KD) were significantly increased only in patients in whom neuroleptic medication had been given within a three-month period before death. When the neuroleptic medication had been withdrawn at least 3 month before death, there was a slight, but not significant, reduction in Bmax values and unchanged KD values. Withdrawal of neuroleptic drugs was followed by a normalization of the KD values within 2 weeks and a slower reduction of Bmax values. There were 6 schizophrenic patients with mainly positive schizophrenic symptoms and 17 patients with mainly negative symptoms; positive schizophrenic symptoms were not related to higher Bmax values. There was no difference in 3H-spiperone binding between patients with and without movement disorders (tardive dyskinesia or extrapyramidal symptoms).
Similar articles
-
Alteration of dopamine receptors in the caudate nucleus and the putamen in schizophrenic brain.Med Biol. 1986;64(6):351-4. Med Biol. 1986. PMID: 2881030
-
Abnormal neuroleptic/dopamine receptors in schizophrenia.Adv Biochem Psychopharmacol. 1980;21:435-42. Adv Biochem Psychopharmacol. 1980. PMID: 6103653
-
Elevation of brain neuroleptic/dopamine receptors in schizophrenia.Am J Psychiatry. 1980 Feb;137(2):191-7. doi: 10.1176/ajp.137.2.191. Am J Psychiatry. 1980. PMID: 6101525
-
Dopamine D2 receptors in substantia nigra in schizophrenia.Brain Res. 1984 May 7;299(1):152-4. doi: 10.1016/0006-8993(84)90798-4. Brain Res. 1984. PMID: 6144367
-
Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S76-80. Can J Psychiatry. 1994. PMID: 7874668 Review.
Cited by
-
Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution.Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):274-80. doi: 10.1007/s00406-006-0661-7. Eur Arch Psychiatry Clin Neurosci. 2006. PMID: 16788768
-
Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells.Psychopharmacology (Berl). 1995 Oct;121(3):373-8. doi: 10.1007/BF02246077. Psychopharmacology (Berl). 1995. PMID: 8584620
-
Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.Mov Disord. 2014 Aug;29(9):1125-33. doi: 10.1002/mds.25909. Epub 2014 May 16. Mov Disord. 2014. PMID: 24838395 Free PMC article.
-
Hippocampal neurons in schizophrenia.J Neural Transm (Vienna). 2002 May;109(5-6):891-905. doi: 10.1007/s007020200073. J Neural Transm (Vienna). 2002. PMID: 12111476 Free PMC article. Review.
-
Management of Tardive Syndrome: Medications and Surgical Treatments.Neurotherapeutics. 2020 Oct;17(4):1694-1712. doi: 10.1007/s13311-020-00898-3. Neurotherapeutics. 2020. PMID: 32720245 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical